Kiadis plans IPO to fund immunotherapy for blood cancers
This article was originally published in Scrip
Executive Summary
Dutch biotech Kiadis Pharma, which is developing T-cell immunotherapy treatments for blood cancers, says it plans to raise new funds through an IPO of its shares on the Euronext in Amsterdam and Brussels.